Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $2,358,215.08 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $34.84, for a total value of $2,358,215.08. Following the completion of the sale, the chief operating officer now directly owns 751,243 shares of the company’s stock, valued at $26,173,306.12. This represents a 8.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $44.71, for a total value of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45.

Hims & Hers Health Trading Down 8.8 %

Hims & Hers Health stock opened at $29.11 on Friday. The stock has a market cap of $6.47 billion, a PE ratio of 66.15 and a beta of 1.37. The stock has a 50-day moving average price of $39.88 and a 200 day moving average price of $29.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on HIMS shares. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Needham & Company LLC boosted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Bank of America upped their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Piper Sandler upped their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $37.31.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. lifted its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at about $38,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.